Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,319
datasets available to search
ShareScore release 0.9.0
Dataset results
1,319 results for “crohns disease”
Development of a machine learning model to predict non- durable response to anti-TNF therapy in Crohn's disease using transcriptome imputed from genotypes
<p>This is the expression value predicted using PrediXcan version 7 to find a gene feature that can distinguish between patients with and without effect on infliximab.</p> <p>Among the various tissue models provided by PrediXcan v7, three models were selected and used: whole blood, Colon transverse, and terminal ileum of small intestine, and the predicted gene counts of each model were 6,294, 5,612 and 3,107.</p> <p>For each of the three models, predicted gene expression values and phenotype information per sample were submitted.</p>
STORMS checklist: Dysbiosis of the enteric microbiota due to Crohn's disease treatment associated with MAIT cell activation
<p>STORMS checklist initiative to standardize reporting of human microbiome research, regarding submission to peer-reviewed journal.</p>
Microbiota Study Crohn's Disease AG Chang
<p>We have investigated a Crohn’s disease (CD) cohort by our multi-parameter microbiota flow cytometry approach to characterise the microbiota on single-cell level for attributes of the disease. The microbiota is isolated from stool samples and stained according to the published protocol for (a) host immunoglobulins IgA1, IgA2, IgM, IgG and (b) agglutinin binding to mannose, galactose or N-Acetyl-glucosamine surface sugar moieties. For all samples we also determined the microbiome composition by 16S rRNA (V3-V4) sequencing on the illumina MiSeq platform. We provide the raw .fcs and FASTQ files of 64 CD patients distributed into two cohorts (55) individuals in cohort 1, 19 individuals in cohort 2). Cohort 2 has two samples for two timepoints.</p> <p>For comparison we additionally analysed 55 healthy donors.</p> <p>All .fcs files were generated on <span>BD Influx®.</span></p> <p> </p> <p>The metadata is collected in the provided meta.csv.</p> <p><span>The staining parameters are summarized in provided panel.csv. </span></p>
RNA-Seq and proteomics of Crohn's disease: Terminal ileum of inflamed and non inflamed paired tissue biopsy
<p>The cause of chronic inflammation manifestations such as inflammatory bowel disease (IBD) is still not yet fully understood. Evidence however points to the convergence of environmental factors, genetic factors, intestinal microbiota and the immune response at the intestinal epithelial surface that consequently leads to a breakdown of barrier function in IBD. An increasing number of theories implicate a dysfunctional intestinal epithelial surface in the pathogenesis of IBD and progression to complicated disease, which contributes significantly to the IBD burden. As yet, the significance of the intestinal epithelial surface in IBD manifestation and progression has not been explored using a systems biology approach, that compares the mucosa of healthy patients to those with IBD. In the context of dyregulation of the epithelial barrier, there is a scarcity of publications that explore the contribution of proteins- the effectors of the cells and RNA message in the pathways affected by CD and in particular the localization of inflammatory response. We aim to evaluate the functional pathways of chronic inflammation at the intestinal epithelial surface using a combination of transcriptomic and proteomic analyses on intestinal epithelial tissue samples from paired inflamed and non-inflammed Crohn's disease (CD) and healthy control subjects. Concordance of several biological pathways from both data sets was found to be altered in CD patients' epithelia when compared to healthy controls. This information could be helpful in identifying novel therapeutic targets that aim to restore barrier function at the intestinal epithelial surface and to guide therapy.</p>
Medication and condition codes used to develop a computable phenotype for Crohn's Disease incident cases
<p>Lists of medication and condition concepts used for Crohn's disease incident case phenotyping as described in my Master's Thesis "Machine Learning Based Prediction of Incident Cases of Crohn’s Disease Using Electronic Health Records From a Large Integrated Health System".</p> <ul> <li>ibd_medication.csv contains medication names, OMOP Concept IDs, RxNorm codes and a flag indicating whether the medication is IBD-specific (i.e., antibiotics and glucocorticoides are marked as unspecific)</li> <li>ibd_conditions.csv contains condition names, OMOP Concept IDs, SNOMED CT codes and a categorical column indicating whether the condition refers to Crohn's Disease (CD), Ulcerative Colitis (UC), or Inflammatory bowel disease unclassified (IBD-U)</li> <li>ibd_symptoms.csv contains symptom names, OMOP Concept IDs, containing symptom group categories, and a flag indicating whether the symptom was added because it is a SNOMED CT descendent code of another code on the list. The list was created based on the IBD symptoms Read Code list provided by Blackwell et. al, 2021, doi:10.1093/ecco-jcc/jjaa146</li> </ul> <p>IBD, Inflammatory Bowel Disease; OMOP, Observational Medical Outcomes Partnership; SNOMED CT, Systematized Nomenclature of Medicine Clinial Terms.</p>
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
ClinicalTrials.gov study NCT03345836. IPD Sharing: YES. Countries: 48. Publications: 7.
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
ClinicalTrials.gov study NCT03627091. IPD Sharing: YES. Countries: 34. Publications: 1.
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
ClinicalTrials.gov study NCT02559713. IPD Sharing: YES. Countries: 1. Publications: 1.
Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease
ClinicalTrials.gov study NCT03706456. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
ClinicalTrials.gov study NCT02620046. IPD Sharing: YES. Countries: 33. Publications: 1.
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
ClinicalTrials.gov study NCT00790933. IPD Sharing: YES. Countries: 10. Publications: 6.
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
ClinicalTrials.gov study NCT02743806. IPD Sharing: YES. Countries: 18. Publications: 1.
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
ClinicalTrials.gov study NCT03279081. IPD Sharing: YES. Countries: 15. Publications: 0.
Triple Combination Therapy in High Risk Crohn's Disease (CD)
ClinicalTrials.gov study NCT02764762. IPD Sharing: YES. Countries: 2. Publications: 1.
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
ClinicalTrials.gov study NCT04186247. IPD Sharing: YES. Countries: 4. Publications: 1.
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
ClinicalTrials.gov study NCT03104413. IPD Sharing: YES. Countries: 43. Publications: 5.
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov study NCT03105128. IPD Sharing: YES. Countries: 44. Publications: 7.
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants
ClinicalTrials.gov study NCT03710486. IPD Sharing: YES. Countries: 2. Publications: 1.
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
ClinicalTrials.gov study NCT02611817. IPD Sharing: YES. Countries: 30. Publications: 1.
RNA-Seq and proteomics of Crohn's disease: Terminal ileum of inflamed and non inflamed paired tissue biopsy
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.